Parameter
| Biomarker | MYC family | Full name | MYC family | Molecular Type | Nucleic acids (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognostic assessment, prediction of chemotherapy efficacy |
| Disease | Small Cell Lung Cancer | Disease Subtypes | / | ||
| Organ | Lung | Test Sample / Technology Platform | Not specified (specific technology platform not specified) | ||
| Pathobiological Mechanisms | Amplification of the MYC family (c-MYC, N-MYC, L-MYC) is associated with the degree of malignancy of SCLC, resulting in rapid tumor growth, early metastasis, and chemotherapy resistance | ||||
| Clinical Availability Status | Research validation / clinical translation: used to screen the beneficiary population of targeted therapy and prognosis judgment | ||||
| Notes and Dynamics | The incidence is about 20% to 40%, and the median survival of amplification-positive patients is shortened and the response to first-line chemotherapy regimens is poor | ||||